Key result
Patient-prosthesis mismatch should be recognized as a contraindication for transcatheter valve-in-valve replacement in patients with severe mitral annular calcification.
Why the study?
Does transcatheter valve-in-valve replacement lead to poor outcomes in patients with severe mitral annular calcification and patient-prosthesis mismatch?
Does transcatheter valve-in-valve replacement lead to poor outcomes in patients with severe mitral annular calcification and patient-prosthesis mismatch?
Patient-prosthesis mismatch should be considered a contraindication for transcatheter valve-in-valve replacement in patients with severe MAC due to the risk of early prosthetic degeneration.
Severe mitral annular calcification (MAC) may represent a challenging issue which can lead to poor outcomes and serious issues such as patient-prosthesis mismatch (PPM). The potential harmful effect of PPM must be prevented through the use of alternative techniques that allow mitral valve replacement with adequately sized bioprostheses in patients with MAC. PPM should be recognized as a contraindication for transcatheter valve-in-valve replacement as it leads to poor outcomes and early prosthetic degeneration.
No takes yet. Share an insight, caveat, or question.
Marin‐Cuartas et al. (2020) conducted an editorial in Severe mitral annular calcification (MAC) and patient-prosthesis mismatch (PPM). Transcatheter valve-in-valve replacement was evaluated. Patient-prosthesis mismatch should be recognized as a contraindication for transcatheter valve-in-valve replacement in patients with severe mitral annular calcification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: